UCB commits $2 billion to Candid's T cell engager program for autoimmune diseases

UCB, a long standing European pharmaceutical company, announced a $2 billion investment in Candid, a biotech focused on T cell engager therapies aimed at autoimmune conditions.

The deal reflects UCB's strategy to expand its pipeline beyond traditional small molecule drugs, leveraging the expertise of biotech veteran Ken Song, who has championed the potential of T cell engagers in this therapeutic area.

The partnership will fund Candid's ongoing preclinical and early clinical programs, with the goal of advancing candidates toward regulatory evaluation, underscoring growing industry interest in cellular immunotherapy for autoimmune disease.